Editorial
A novel biomarker protein panel for lung cancer, a promising first step
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S304-S307
.
(30 December 2018)
Sleep better on combination therapy: SLFN11 predicts response to veliparib and temozolomide in recurrent small cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S308-S311
.
(30 December 2018)
Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S312-S317
.
(30 December 2018)
Treatment of lung adenocarcinoma brain metastases: what is the role of radiotherapy in the age of precision medicine?
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S318-S320
.
(30 December 2018)
Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC “capitulate”?
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S321-S325
.
(30 December 2018)
DARPP-32 and t-DARPP isoform in non-small cell lung cancer (NSCLC): could they drive patients’ clinical management and be a therapeutic target?
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S326-S328
.
(30 December 2018)
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S329-S333
.
(30 December 2018)
Two are better than one on progression through MET mechanism for EGFR+ NSCLC patients
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S334-S335
.
(30 December 2018)
Interplay between immune cells in lung cancer: beyond T lymphocytes
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S336-S340
.
(30 December 2018)
Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S341-S345
.
(30 December 2018)
Specific copy number changes as potential predictive markers for adjuvant chemotherapy in non-small cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S346-S348
.
(30 December 2018)
The combination strategies will be ready the right first-line choice for squamous lung cancer patients?
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S349-S351
.
(30 December 2018)
Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S352-S355
.
(30 December 2018)
Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S356-S357
.
(30 December 2018)
Tumor mutational burden as predictive factor of response to immunotherapy
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S358-S361
.
(30 December 2018)
Old myths about old patients: the case of non-small cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S362-S363
.
(30 December 2018)
BRMS1 expression in resected lung adenocarcinoma
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S364-S366
.
(30 December 2018)
Editorial for “Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse”
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S367-S369
.
(30 December 2018)
Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S370-S372
.
(30 December 2018)
Aromatase inhibitors combined with aspirin to prevent lung cancer in preclinical models
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S373-S376
.
(30 December 2018)
Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer—driving down a precarious road in driver-mutated lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S377-S380
.
(30 December 2018)
STAT3 cyclic oligonucleotide decoy—a new therapeutic avenue for NSCLC?
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S381-S384
.
(30 December 2018)
Role of immune checkpoint blockers in patients with EGFR mutation
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S385-S387
.
(30 December 2018)
Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy—fortune favours the bold
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S388-S392
.
(30 December 2018)
Meet the Professor
Raymond U. Osarogiagbon: lung cancer is a global challenge that needs our close cooperation!
Translational Lung Cancer Research
2018;
7
(Suppl 4)
:S393-S396
.
(30 December 2018)
Disclosure:
The supplement was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding.
